Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3569-3571

  Rodríguez, M Mar ^a   Calvo, Enrique ^a   Mariné, Marçal ^a   Pastor, F Javier ^a   Fernandez Ballart, Joan ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; KIDNEY PARENCHYMA; MALE; MOUSE; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SURVIVAL TIME; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-GAMMA; MALE; MICE; RHIZOPUS; ZYGOMYCOSIS;

EID: 67749127606     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00456-09     Document Type: Article

References (20)

1. Abzug, M. J., and T. J. Walsh. 2004. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr. Infect. Dis. J. 23:769-773.
2. Chayakulkeeree, M., M. A. Ghannoum, and J. R. Perfect. 2006. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25:215-229.
3. Clemons, K. V., J. E. Lutz, and D. A. Stevens. 2001. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob. Agents Chemother. 45:686-689.
4. Deepe, G. S., Jr., and R. Gibbons. 2000. Recombinant murine granulocytemacrophage colony-stimulating factor modulates the course of pulmonary histoplasmosis in immunocompetent and immunodeficient mice. Antimicrob. Agents Chemother. 44:3328-3336.
5. Garcia-Diaz, J. B., L. Palau, and G. A. Pankey. 2001. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocytemacrophage colony-stimulating factor. Clin. Infect. Dis. 32:166-170.
6. Gil-Lamaignere, C., M. Simitsopoulou, E. Roilides, A. Maloukou, R. M. Winn, and T. J. Walsh. 2005. Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J. Infect. Dis. 191:1180-1187.
7. Gleissner, B., A. Schilling, I. Anagnostopolous, I. Siehl, and E. Thiel. 2004. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma 45:1351-1360.
8. Gonzalez, C. E., D. R. Couriel, and T. J. Walsh. 1997. Disseminated zygomycosis in a neutropenic patient: succesful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin. Infect. Dis. 24:192-196.
9. Greenberg, R. N., K. Mullane, J. A. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
10. Hübel, K., D. C. Dale, and W. C. Liles. 2002. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-γ. J. Infect. Dis. 185:1490-1501.
11. Ibrahim, A. S., V. Avanessian, B. Spellberg, and J. E. Edwards, Jr. 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47:3343-3344.
12. Ibrahim, A. S., T. Gebremariam, M. I. Husseiny, D. A. Stevens, Y. Fu, J. E. Edwards, Jr., and B. Spellberg. 2008. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob. Agents Chemother. 52:1573-1576.
13. Ibrahim, A. S., T. Gebremariam, J. A. Schwartz, J. E. Edwards, Jr., and B. Spellberg. 2009. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob. Agents Chemother. 53:772-775.
14. Mastroianni, A. 2004. Paranasal sinus mucormycosis in an immunocompetent host: efficacy and safety of combination therapy with liposomal amphotericin B and adjuvant rHuGM-CSF. Infez. Med. 12:278-283.
15. Reference deleted.
16. Rodríguez, M. M., C. Serena, M. Mariné, F. J. Pastor, and J. Guarro. 2008. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52:3786-3788.
17. Rogers, T. R. 2008. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother. 61:35-39.
18. Safdar, A. 2007. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 12:2-6.
19. Simitsopoulou, M., C. Gil-Lamaignere, N. Avramidis, A. Maloukou, S. Lekkas, E. Havlova, L. Kaurounaki, D. Loebenberg, and E. Roilides. 2004. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48:3801-3805.
20. Tobón, A. M., M. Arango, D. Fernández, and A. Restrepo. 2003. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36:1488-1491.